Genentech Pays $55M Upfront for Earendil’s AI-Built Oncology Bispecifics
- Genentech will pay Earendil Labs $55 million upfront, with up to about $1.445 billion in development, regulatory and sales milestones, plus tiered royalties.
- Earendil leads antibody discovery and early clinical work on pre-agreed target pairs using its AI antibody-generation platform; Genentech takes over global development and commercialization.
💡 Points
Roche is buying optionality on target combinations, not a single asset: a small upfront against a milestone-heavy tail is the classic platform structure, and it limits the downside if the AI-generated molecules disappoint. The signal is that big pharma still wants bispecific capacity in oncology after the PD-1×VEGF rush, and is willing to source it from AI-native shops.
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil… ↗